{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:49:24Z","timestamp":1791532164376,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.05.042","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:09:07Z","timestamp":1780301347000},"page":"1248.e1-1248.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase 1b Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8447-9607","authenticated-orcid":false,"given":"Shukaib","family":"Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-4314","authenticated-orcid":false,"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8578-1226","authenticated-orcid":false,"given":"Sunil H.","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-5184","authenticated-orcid":false,"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0495-909X","authenticated-orcid":false,"given":"Wenyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanke","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8779-3338","authenticated-orcid":false,"given":"Annemarie","family":"Lekkerkerker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-9231","authenticated-orcid":false,"given":"Chin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melicent C.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.05.042_bib0001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and other HSCT-related major complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.05.042_bib0002","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrgastro.2017.126","article-title":"Acute graft-versus-host disease of the gut: considerations for the gastroenterologist","volume":"14","author":"Naymagon","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jtct.2026.05.042_bib0003","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease\u2014biologic, process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.042_bib0004","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]","article-title":"GVHD prophylaxis","author":"Boelens","year":"2024"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.042_bib0005","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.042_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/hematology.2025000737","article-title":"New age GVHD prophylaxis regimens: what works for what donor and why","volume":"2025","author":"Gooptu","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.042_bib0007","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jtct.2026.05.042_bib0008","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.042_bib0009","unstructured":"Orencia (abatacept). Package insert. Bristol-Myers Squibb Company; 2021. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125118s241lbl.pdf. Accessed January 20, 2026."},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.042_bib0010","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2021-150742","volume":"138","author":"Kean","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.042_bib0011","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.042_bib0012","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.042_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2026.102749","article-title":"Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY","volume":"100","author":"Liga","year":"2026","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.042_bib0014","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192195","article-title":"The role of IL-22 in intestinal health and disease","volume":"217","author":"Keir","year":"2020","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.042_bib0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.intimp.2004.01.016","article-title":"IL 22, a Th1 cytokine that targets the pancreas and select other peripheral tissues","volume":"4","author":"Gurney","year":"2004","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.042_bib0016","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nri3766","article-title":"The IL-20 subfamily of cytokines\u2013from host defence to tissue homeostasis","volume":"14","author":"Rutz","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2026.05.042_bib0017","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature16460","article-title":"Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration","volume":"528","author":"Lindemans","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2026.05.042_bib0018","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1172\/JCI99261","article-title":"Survival signal REG3 prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2026.05.042_bib0019","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2017-01-762658","article-title":"Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease","volume":"130","author":"Dudakov","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.042_bib0020","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.bbmt.2019.06.002","article-title":"IL-22 accelerates thymus regeneration via Stat3\/Mcl-1 and decreases chronic graft-versus-host disease in mice after allotransplants","volume":"25","author":"Pan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.042_bib0021","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood.2021015111","article-title":"A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","volume":"141","author":"Ponce","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.042_bib0022","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bcp.2018.03.031","article-title":"Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases","volume":"152","author":"Stefanich","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jtct.2026.05.042_bib0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt.1164","article-title":"Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury","volume":"105","author":"Rothenberg","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.042_bib0024","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/gutjnl-2022-328387","article-title":"Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis","volume":"72","author":"Wagner","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jtct.2026.05.042_bib0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.042_bib0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.042_bib0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.069559","article-title":"Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients","volume":"98","author":"Labrador","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.042_bib0028","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.cgh.2024.11.013","article-title":"A randomized phase II study of efmarodocokin alfa, an interleukin-22 agonist, versus vedolizumab in patients with ulcerative colitis","volume":"23","author":"Danese","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.042_bib0029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CCM.0000000000005716","article-title":"Astegolimab or efmarodocokin alfa in patients with severe COVID-19 pneumonia: a randomized, phase 2 trial","volume":"51","author":"Waters","year":"2023","journal-title":"Crit Care Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:58:26Z","timestamp":1791529106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726004434"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.042","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1b Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}